SMS 201-995 treatment and advanced intestinal cancer: a pilot study.
The hypothesis that somatostatin, a compound with antitrophic effects on the gastrointestinal tract, may affect beneficially the progression of advanced intestinal cancer has been tested in a small pilot study. Ten patients, four with advanced pancreatic cancer, four with advanced colorectal cancer and two with gastric cancer, were treated with a long-acting analogue of somatostatin, SMS 201-995, 50, 100 micrograms subcutaneously twice daily. There were no clinical, radiological or biochemical indicators of a response to this treatment. There are no indications from this study that hormonal manipulation alters the rate of growth of advanced gastrointestinal cancer.
Savage
A P
AP
Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Calam
J
J
Wood
C B
CB
Bloom
S R
SR
D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007414:Intestinal Neoplasms / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D010865:Pilot Projects; D013274:Stomach Neoplasms / Q000188:drug therapy
D015282:Octreotide